

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14538 A2

(51) International Patent Classification⁷: **C12N 15/00**

(81) **Designated States (national):** AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.

(21) International Application Number: **PCT/US00/22613**

(84) **Designated States (regional):** European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(22) International Filing Date: 11 August 2000 (11.08.2000)

Published:

(25) Filing Language: English

— *Without international search report and to be republished upon receipt of that report.*

(26) Publication Language: English

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(30) Priority Data:

60/151,224 26 August 1999 (26.08.1999) US

60/172,128 17 December 1999 (17.12.1999) US

(71) Applicant: CALGENE LLC [US/US]; 1920 Fifth Street, Davis, CA 95616 (US).

(72) Inventor: FILLATTI, Joanne, J.; 36757 Russell Blvd., Davis, CA 95616 (US).

(74) Agent: EAGLE, Alissa, M.; Calgene LLC, 1920 Fifth Street, Davis, CA 95616 (US).



WO 01/14538 A2

(54) Title: NUCLEIC ACID SEQUENCES AND METHODS OF USE FOR THE PRODUCTION OF PLANTS WITH MODIFIED POLYUNSATURATED FATTY ACIDS

(57) Abstract: By this invention, novel nucleic acid sequences are provided, wherein said nucleic acid sequence is a genomic sequence of a plant desaturase encoding sequence. Also provided in the present invention are the promoter and intron sequences of the desaturase genomic sequences. Furthermore, recombinant DNA constructs employing the polynucleotide sequences are provided. The instant invention also provides methods for the modification of fatty acid compositions in host plant cells.

**NUCLEIC ACID SEQUENCES AND METHODS OF USE FOR THE
PRODUCTION OF PLANTS WITH MODIFIED POLYUNSATURATED FATTY
ACIDS**

5

INTRODUCTION

This application claims priority to U.S. Provisional Application Serial No. 60/151,224 filed August 26, 1999 and U.S. Provisional Application Serial No. 60/172,128 filed December 17, 1999.

10

Technical Field

The present invention is directed to nucleic acid sequences and constructs, and methods related thereto.

15 **Background**

Plant oils are used in a variety of applications. Novel vegetable oils compositions and/or improved means to obtain oils compositions, from biosynthetic or natural plant sources, are needed. Depending upon the intended oil use, various different fatty acid compositions are desired.

20 One means postulated to obtain such oils and/or modified fatty acid compositions is through the genetic engineering of plants. However, it is necessary to identify the appropriate nucleic acid sequences which are capable of producing the desired phenotypic result, regulatory regions capable of directing the correct application of such sequences, and the like.

Higher plants appear to synthesize fatty acids via a common metabolic pathway (fatty acid synthetase pathway). In developing seeds, where fatty acids are attached to glycerol backbones, forming triglycerides, for storage as a source of energy for further germination, the FAS pathway is located in the proplastids. The first committed step is

5 the formation of acetyl-ACP (acyl carrier protein) from acetyl-CoA and ACP catalyzed by the enzyme, acetyl-CoA:ACP transacylase (ATA). Elongation of acetyl-ACP to 16- and 18- carbon fatty acids involves the cyclical action of the following sequence of reactions: condensation with a two-carbon unit from malonyl-ACP to form a β -ketoacyl-ACP (β -ketoacyl-ACP synthase), reduction of the keto-function to an alcohol (β -ketoacyl-ACP

10 reductase), dehydration to form an enoyl-ACP (β -hydroxyacyl-ACP dehydrase), and finally reduction of the enoyl-ACP to form the elongated saturated acyl-ACP (enoyl-ACP reductase). β -ketoacyl-ACP synthase I, catalyzes elongation up to palmitoyl-ACP (C16:0), whereas β -ketoacyl-ACP synthase II catalyzes the final elongation to stearoyl-ACP (C18:0). Common plant unsaturated fatty acids, such as oleic, linoleic and a-

15 linolenic acids found in storage triglycerides, originate from the desaturation of stearoyl-ACP to form oleoyl-ACP (C18:1) in a reaction catalyzed by a soluble plastid Δ -9 desaturase (also often referred to as "stearoyl-ACP desaturase"). Molecular oxygen is required for desaturation in which reduced ferredoxin serves as an electron co-donor.

Additional desaturation is effected sequentially by the actions of membrane bound Δ -12

20 desaturase and Δ -15 desaturase. These "desaturases" thus create mono- or polyunsaturated fatty acids respectively.

Obtaining nucleic acid sequences capable of producing a phenotypic result in FAS, desaturation and/or incorporation of fatty acids into a glycerol backbone to produce an oil is subject to various obstacles including but not limited to the identification of

25 metabolic factors of interest, choice and characterization of an enzyme source with useful

kinetic properties, purification of the protein of interest to a level which will allow for its amino acid sequencing, utilizing amino acid sequence data to obtain a nucleic acid sequence capable of use as a probe to retrieve the desired DNA sequence, and the preparation of constructs, transformation and analysis of the resulting plants.

5 Thus, additional nucleic acid targets and methods for modifying fatty acid compositions are needed. In particular, constructs and methods to produce a variety of ranges of different fatty acid compositions are needed.

SUMMARY OF THE INVENTION

10

The present invention is generally directed to genomic desaturase polynucleotides, and in particular to genomic desaturase polynucleotides which encode enzymes that catalyze the insertion of a double bond into a fatty acyl moiety at the twelfth ($\Delta 12$ desaturase or *fad2*) or fifteenth ($\Delta 15$ desaturase or *fad3*) carbon position in a fatty acyl chain as counted from the carboxyl terminus. Further, the present invention provides isolated non-coding regions of such genomic polynucleotide sequences, particularly including the introns, and promoter regions. Specific oligonucleotides are provided which include partial or complete sequences which are derived from $\Delta 12$ and $\Delta 15$ desaturase promoter and intron sequences. Although the sequences disclosed herein are obtained 15 from soybean plants, it is contemplated that additional sequences can be derived from intron and promoter regions of desaturase genomic polynucleotide sequences which are homologous or have identity to the soybean desaturase sequences. Such additional desaturase sequences can be obtained using standard methods described below from a 20 variety of plant sources, in particular oilseed crops.

It is also an aspect of the present invention to provide recombinant DNA constructs which can be used for the modification of the fatty acid composition in a plant and in particular, to modify the transcription or transcription and translation (expression) of desaturase genes or proteins, such as $\Delta 12$ and $\Delta 15$ desaturase. The invention is 5 particularly directed to DNA constructs which include sequences which are derived from the intron or promoter regions of a genomic clone wherein said sequences are in a sense or antisense orientation in a DNA construct. These DNA constructs are then used to transform or transfect host cells to produce plants with modified levels of fatty acids, particularly modified levels of oleic, linoleic and linolenic acid. It is particularly 10 contemplated to provide constructs and methods for down regulating $\Delta 12$ and $\Delta 15$ desaturase gene expression, so as to increase the levels of oleic acid and to decrease the levels of linoleic acid and linolenic acid. It is particularly contemplated to alter the fatty acid composition in seed tissue of oilseed crops.

The modified plant cells, plants, seeds and oils obtained by the expression of the 15 $\Delta 12$ and $\Delta 15$ desaturase polynucleotides are also considered part of the invention. Further, it is contemplated to produce oil compositions with specific relative levels of each fatty acid. One preferred embodiment comprises at least about 80 - 85% oleic acid, no more than about 1 - 2% linoleic acid, and no more than about 1 - 3% linolenic acid; and a second preferred embodiment comprising at least about 50-75% oleic acid, at least 20 about 10 - 30% linoleic acid, and no more than about 3% linolenic acid.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to genomic desaturase sequences, particularly the 25 isolated non-coding sequences from genomic fatty acid desaturase nucleic acid sequences from host cell sources. A desaturase sequence of this invention includes any nucleic acid

genomic sequence, including all non-coding regions, encoding amino acids from a source, such as a protein, polypeptide or peptide, obtainable from a cell source, which is capable of catalyzing the insertion of a double bond into a fatty acyl moiety in a plant host cell, i.e., in vivo, or in a plant cell-like environment, i.e. in vitro. As will be described in more detail below, specific genomic polynucleotide sequences encoding enzymes which add double bonds at the twelfth ($\Delta 12$ desaturase) and fifteenth ($\Delta 15$ desaturase) carbon positions in a fatty acyl chain as counted from the carboxyl terminus are provided. In addition, provided herein are specific non-coding regions of such genomic sequences.

The term "non-coding" refers to sequences of polynucleotides that do not encode part or all of an expressed protein. Non-coding sequences include but are not limited to introns, promoter regions, and 5' untranslated regions.

The term "intron" as used herein refers to the normal sense of the term as meaning a segment of polynucleotides, usually DNA, that does not encode part or all of an expressed protein.

The term "exon" as used herein refers to the normal sense of the term as meaning a segment of polynucleotides, usually DNA, that encodes part or all of an expressed protein.

Thus, the term "intron" refers to gene regions that are transcribed into RNA molecules, but which are spliced out of the RNA before the RNA is translated into a protein. As contrasted to the term "exon" which refers to gene regions that are transcribed into RNA and subsequently translated into proteins.

As set forth in detail in the sequence listing and the examples, genomic $\Delta 12$ desaturase and $\Delta 15$ desaturase sequences and intron and promoter regions obtained from such sequences are provided herein. In particular, two $\Delta 12$ desaturase genomic clones

were identified and are set forth in SEQ ID NOS:1 and 23. A single Δ 15 desaturase genomic clone was identified and is set forth in SEQ ID NO:3. A single intron region was obtained from each of the Δ 12 desaturase genomic clones with the sequences provided in SEQ ID NOS:2 and 24, respectively. The promoter region from each of the 5 Δ 12 desaturase genomic clones are respectively included in SEQ ID NO:1 (base pairs 1 - 1094) and SEQ ID NO:23 (base pairs 1 - 1704). The Δ 15 desaturase included seven introns in the coding region (set forth as SEQ ID NOS:4, 5, 6, 7, 8, 25 and 26). In addition, preliminary results suggest that there is an additional intron within the 5' untranslated region.

10 Although the sequences described herein are obtained from soybean, it is contemplated that intron and promoter regions can be obtained from desaturase genomic polynucleotide sequences which are homologous or have identity to the soybean desaturase sequences. In particular, sequences can be obtained from other plant sources and particularly from oilseed crops. Such genomic sequences can be obtained using 15 standard methods, certain of which are described below.

 The sequences of the present invention can be used to modify the fatty acid composition in a plant (see Example 3 and Table I). In particular, it is shown that sense and antisense suppression can be used to obtain broad ranges in the levels of oleic, linoleic and linolenic acid. In particular, it is shown that levels of oleic acid can range 20 from about 26 to 80 %, levels of linoleic acid can range from about 2.97 to 49.92 % and levels of linolenic acid can range from about 3.38 to 8.81%. However, these are merely representative of the broad range that can be achieved. Moreover, it is contemplated that combinations of the sequences could be used to achieve additional fatty acid compositions. Certain compositions are preferred based on the intended use of the oil.

One preferred composition includes at least about 50 - 75% oleic acid, at least about 10 - 30% linoleic acid and no more than about 3% linolenic acid. A particularly preferred embodiment includes at least about 60 - 70% oleic acid, at least about 15 - 20% linoleic acid and no more than about 3% linolenic acid.

5 Although the examples set forth herein utilize sense or antisense suppression to downregulate the gene of interest, it is contemplated that other means of modifying gene expression can be used. In particular, it is contemplated that gene expression can be down regulated using DNA binding proteins which can be designed to specifically bind to the non-coding regions identified herein or that ribozymes can be designed to cleave such 10 non-coding regions. In addition, as described below, other methods of downregulation of gene expression which are well known in the art are contemplated and can be used with the sequences of the present invention.


Isolated Polynucleotides, Proteins, and Polypeptides

15 A first aspect of the present invention relates to isolated desaturase polynucleotides. The polynucleotide sequences of the present invention include isolated polynucleotides that are obtainable from genomic nucleic acid sequences.

20 The invention provides a polynucleotide sequence identical over its entire length to each sequence as set forth in the Sequence Listing. The polynucleotide includes non-coding sequences, including for example, but not limited to, non-coding 5' and 3' sequences, such as the transcribed, untranslated sequences, termination signals, ribosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and 25 additional coding sequence that encodes additional amino acids. For example, a marker sequence can be included to facilitate the purification of the fused polypeptide.

Polynucleotides of the present invention also include polynucleotides comprising a structural gene and the naturally associated sequences that control gene expression.

The invention also includes polynucleotides of the formula:



5 wherein, at the 5' end, X is hydrogen, and at the 3' end, Y is hydrogen or a metal, R₁ and R₃ are any nucleic acid residue, n is an integer between 1 and 3000, preferably between 1 and 1000 and R₂ is a nucleic acid sequence of the invention, particularly a nucleic acid sequence selected from the group set forth in the Sequence Listing and preferably SEQ ID NOs: 1 - 8, and 23 - 29. In the formula, R₂ is oriented so that its 5' end residue is at the
10 left, bound to R₁, and its 3' end residue is at the right, bound to R₃. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

Further preferred embodiments of the invention that are at least 50%, 60%, or 70% identical over their entire length to a polynucleotide of the invention, and polynucleotides
15 that are complementary to such polynucleotides. More preferable are polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide of the invention and polynucleotides that are complementary thereto. In this regard, polynucleotides at least 90% identical over their entire length are particularly preferred, those at least 95% identical are especially preferred. Further, those with at least 97%
20 identity are highly preferred and those with at least 98% and 99% identity are particularly highly preferred, with those at least 99% being the most highly preferred.

Preferred embodiments are polynucleotides that are obtained from genomic polynucleotide sequences and set forth in the Sequence Listing.

The invention further relates to polynucleotides that hybridize to the above-
25 described sequences. In particular, the invention relates to polynucleotides that hybridize

under stringent conditions to the above-described polynucleotides. As used herein, the

terms "stringent conditions" and "stringent hybridization conditions" mean that

hybridization will generally occur if there is at least 95% and preferably at least 97%

identity between the sequences. An example of stringent hybridization conditions is

5 overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (150 mM

NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's

solution, 10% dextran sulfate, and 20 micrograms/milliliter denatured, sheared salmon

sperm DNA, followed by washing the hybridization support in 0.1x SSC at approximately

65°C. Other hybridization and wash conditions are well known and are exemplified in

10 Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, cold Spring

Harbor, NY (1989), particularly Chapter 11.

The invention also provides a polynucleotide consisting essentially of a

polynucleotide sequence obtainable by screening an appropriate library containing the

complete gene for a polynucleotide sequence set forth in the Sequence Listing under

15 stringent hybridization conditions with a probe having the sequence of said

polynucleotide sequence or a fragment thereof; and isolating said polynucleotide

sequence. Fragments useful for obtaining such a polynucleotide include, for example,

probes and primers as described herein.

As discussed herein regarding polynucleotide assays of the invention, for example,

20 polynucleotides of the invention can be used as a hybridization probe for RNA, cDNA, or

genomic DNA to isolate full length cDNAs or genomic clones encoding a polypeptide

and to isolate cDNA or genomic clones of other genes that have a high sequence

similarity to a polynucleotide set forth in the Sequence Listing. Such probes will

generally comprise at least 15 bases. Preferably such probes will have at least 30 bases

and can have at least 50 bases. Particularly preferred probes will have between 30 bases and 50 bases, inclusive.

The region of each gene that comprises or is comprised by a polynucleotide sequence set forth in the Sequence Listing may be isolated by screening using a DNA sequence provided in the Sequence Listing to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a polynucleotide of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to identify members of the library which hybridize to the probe. For example, synthetic oligonucleotides are prepared which correspond to the desaturase promoter and intron sequences. In particular, screening of cDNA libraries in phage vectors is useful in such methods due to lower levels of background hybridization.

Typically, a desaturase sequence obtainable from the use of nucleic acid probes will show 60-70% sequence identity between the target desaturase sequence and the encoding sequence used as a probe. However, lengthy sequences with as little as 50-60% sequence identity may also be obtained. The nucleic acid probes may be a lengthy fragment of the nucleic acid sequence, or may also be a shorter, oligonucleotide probe. When longer nucleic acid fragments are employed as probes (greater than about 100 bp), one may screen at lower stringencies in order to obtain sequences from the target sample which have 20-50% deviation (i.e., 50-80% sequence homology) from the sequences used as probe. Oligonucleotide probes can be considerably shorter than the entire nucleic acid sequence encoding an desaturase enzyme, but should be at least about 10, preferably at least about 15, and more preferably at least about 20 nucleotides. A higher degree of sequence identity is desired when shorter regions are used as opposed to longer regions. It may thus be desirable to identify regions of highly conserved amino acid sequence to design oligonucleotide probes for detecting and recovering other related desaturase genes.

Shorter probes are often particularly useful for polymerase chain reactions (PCR), especially when highly conserved sequences can be identified. (See, Gould, *et al.*, *PNAS USA* (1989) 86:1934-1938.).

“Identity”, as is well understood in the art, is a relationship between two or more 5 polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as determined by the match between strings of such sequences. “Identity” can be readily calculated by known methods including, but not limited to, those described in *Computational Molecular 10 Biology*, Lesk, A.M., ed., Oxford University Press, New York (1988); *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M. and Griffin, H.G., eds., Humana Press, New Jersey (1994); *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press (1987); *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., 15 eds., Stockton Press, New York (1991); and Carillo, H., and Lipman, D., *SIAM J Applied Math*, 48:1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available programs. Computer programs which can be used to determine identity between two sequences include, but are not limited to, GCG 20 (Devereux, J., et al., *Nucleic Acids Research* 12(1):387 (1984); suite of five BLAST programs, three designed for nucleotide sequences queries (BLASTN, BLASTX, and TBLASTX) and two designed for protein sequence queries (BLASTP and TBLASTN) (Coulson, *Trends in Biotechnology*, 12: 76-80 (1994); Birren, *et al.*, *Genome Analysis*, 1: 543-559 (1997)). The BLAST X program is publicly available from NCBI and other 25 sources (*BLAST Manual*, Altschul, S., *et al.*, NCBI NLM NIH, Bethesda, MD 20894;

Altschul, S., *et al.*, *J. Mol. Biol.*, 215:403-410 (1990)). The well known Smith Waterman algorithm can also be used to determine identity.

Parameters for polypeptide sequence comparison typically include the following:

Algorithm: Needleman and Wunsch, *J. Mol. Biol.* 48:443-453 (1970)

5 Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci USA* 89:10915-10919 (1992)

Gap Penalty: 12

Gap Length Penalty: 4

A program which can be used with these parameters is publicly available as the

10 "gap" program from Genetics Computer Group, Madison Wisconsin. The above parameters along with no penalty for end gap are the default parameters for peptide comparisons.

Parameters for polynucleotide sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol. Biol.* 48:443-453 (1970)

15 Comparison matrix: matches = +10; mismatches = 0

Gap Penalty: 50

Gap Length Penalty: 3

A program which can be used with these parameters is publicly available as the

"gap" program from Genetics Computer Group, Madison Wisconsin. The above

20 parameters are the default parameters for nucleic acid comparisons.

For immunological screening, antibodies to the protein can be prepared by injecting rabbits or mice with the purified protein or portion thereof, such methods of preparing antibodies being well known to those in the art. Either monoclonal or polyclonal antibodies can be produced, although typically polyclonal antibodies are more useful for gene isolation. Western analysis may be conducted to determine that a related

protein is present in a crude extract of the desired plant species, as determined by cross-reaction with the antibodies to the encoded proteins. When cross-reactivity is observed, genes encoding the related proteins are isolated by screening expression libraries representing the desired plant species. Expression libraries can be constructed in a variety 5 of commercially available vectors, including lambda gt11, as described in Sambrook, *et al. (Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).*

Plant Constructs and Methods of Use

10

Of particular interest is the use of the polynucleotide sequences in recombinant DNA constructs to direct the transcription of the desaturase genomic sequences of the present invention in a host plant cell. The expression constructs generally comprise a promoter functional in a host plant cell operably linked to a nucleic acid sequence of the 15 present invention and a transcriptional termination region functional in a host plant cell.

Those skilled in the art will recognize that there are a number of promoters which are functional in plant cells, and have been described in the literature. Chloroplast and plastid specific promoters, chloroplast or plastid functional promoters, and chloroplast or plastid operable promoters are also envisioned.

20

One set of promoters are constitutive promoters such as the CaMV35S or FMV35S promoters that yield high levels of expression in most plant organs. Enhanced or duplicated versions of the CaMV35S and FMV35S promoters are useful in the practice of this invention (Odell, *et al. (1985) Nature 313:810-812; Rogers, U.S. Patent Number 5,378, 619*). In addition, it may also be preferred to bring about expression of the 25 sequences of the present invention in specific tissues of the plant, such as leaf, stem, root,

tuber, seed, fruit, etc., and the promoter chosen should have the desired tissue and developmental specificity.

Of particular interest is the expression of the nucleic acid sequences of the present invention from transcription initiation regions which are preferentially expressed in a plant seed tissue. Examples of such seed preferential transcription initiation sequences include those sequences derived from sequences encoding plant storage protein genes or from genes involved in fatty acid biosynthesis in oilseeds. Examples of such promoters include the 5' regulatory regions from such genes as napin (Kridlet *et al.*, *Seed Sci. Res.* 1:209:219 (1991)), phaseolin, zein, soybean trypsin inhibitor, ACP, stearoyl-ACP desaturase, soybean α' subunit of β -conglycinin (soy 7s, (Chen *et al.*, *Proc. Natl. Acad. Sci.*, 83:8560-8564 (1986))) and oleosin.

It may be advantageous to direct the localization of proteins conferring desaturase to a particular subcellular compartment, for example, to the mitochondrion, endoplasmic reticulum, vacuoles, chloroplast or other plastidic compartment. For example, where the genes of interest of the present invention will be targeted to plastids, such as chloroplasts, for expression, the constructs will also employ the use of sequences to direct the gene to the plastid. Such sequences are referred to herein as chloroplast transit peptides (CTP) or plastid transit peptides (PTP). In this manner, where the gene of interest is not directly inserted into the plastid, the expression construct will additionally contain a gene encoding a transit peptide to direct the gene of interest to the plastid. The chloroplast transit peptides may be derived from the gene of interest, or may be derived from a heterologous sequence having a CTP. Such transit peptides are known in the art. See, for example, Von Heijne *et al.* (1991) *Plant Mol. Biol. Rep.* 9:104-126; Clark *et al.* (1989) *J. Biol. Chem.* 264:17544-17550; della-Cioppa *et al.* (1987) *Plant Physiol.* 84:965-968;

Romer *et al.* (1993) *Biochem. Biophys. Res Commun.* 196:1414-1421; and, Shah *et al.* (1986) *Science* 233:478-481.

Depending upon the intended use, the constructs may contain the entire genomic nucleic acid sequence or a particular non-coding region of such a sequence or a portion of such sequences. For example, where antisense inhibition of a given desaturase protein is desired, the entire sequence is not required. Furthermore, where desaturase sequences used in constructs are intended for use as probes, it may be advantageous to prepare constructs containing only a particular portion of a desaturase sequence, for example a sequence which encodes a highly conserved desaturase region.

The skilled artisan will recognize that there are various methods for the inhibition of expression of endogenous sequences in a host cell. Such methods include, but are not limited to, antisense suppression (Smith, *et al.* (1988) *Nature* 334:724-726), co-suppression (Napoli, *et al.* (1989) *Plant Cell* 2:279-289), ribozymes (PCT Publication WO 97/10328), combinations of sense and antisense (Waterhouse, *et al.* (1998) *Proc. Natl. Acad. Sci. USA* 95:13959-13964), promoter silencing (Park, *et al.* (1996) *Plant J.* 9(2):183-194), DNA binding proteins (Beerli, *et al.* (1997) *Proc. Natl. Acad. Sci. USA*, 95:14628-14633; and Liu, *et al.* (1998) *Proc. Natl. Acad. Sci. USA*, 94:5525-5530). Methods for the suppression of endogenous sequences in a host cell typically employ the transcription or transcription and translation of at least a portion of the sequence to be suppressed. Such sequences may be homologous to coding as well as non-coding regions of the endogenous sequence.

Regulatory transcript termination regions may be provided in plant expression constructs of this invention as well. Transcript termination regions may be provided by the DNA sequence encoding the desaturase or a convenient transcription termination region derived from a different gene source, for example, the transcript termination region

which is naturally associated with the transcript initiation region. The skilled artisan will recognize that any convenient transcript termination region which is capable of terminating transcription in a plant cell may be employed in the constructs of the present invention.

5 Alternatively, constructs may be prepared to direct the expression of the desaturase sequences directly from the host plant cell plastid. Such constructs and methods are known in the art and are generally described, for example, in Svab, *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:8526-8530 and Svab and Maliga (1993) *Proc. Natl. Acad. Sci. USA* 90:913-917 and in U.S. Patent Number 5,693,507.

10 A plant cell, tissue, organ, or plant into which the recombinant DNA constructs containing the expression constructs have been introduced is considered transformed, transfected, or transgenic. A transgenic or transformed cell or plant also includes progeny of the cell or plant and progeny produced from a breeding program employing such a transgenic plant as a parent in a cross and exhibiting an altered phenotype resulting from 15 the presence of a desaturase nucleic acid sequence.

Plant expression or transcription constructs having a desaturase polynucleotide of the present invention as the DNA sequence of interest for increased or decreased expression thereof may be employed with a wide variety of plant life, particularly, plant life involved in the production of vegetable oils for edible and industrial uses. Most 20 especially preferred are temperate oilseed crops. Plants of interest include, but are not limited to, rapeseed (Canola and High Erucic Acid varieties), sunflower, safflower, cotton, soybean, peanut, coconut and oil palms, and corn. Depending on the method for introducing the recombinant constructs into the host cell, other DNA sequences may be required. Importantly, this invention is applicable to dicotyledons and monocotyledons

species alike and will be readily applicable to new and/or improved transformation and regulation techniques.

Of particular interest, is the use of plant desaturase promoter and/or intron constructs in plants to produce plants or plant parts, including, but not limited to leaves, stems, roots, reproductive, and seed, with a modified fatty acid composition. Of particular interest in the desaturase promoter and/or intron constructs is the use of the promoter and/or intron sequences of the Δ -12 and Δ -15 desaturase genomic sequences in sense or antisense orientations for the modification of fatty acid compositions in host cells.

10 The polynucleotides of the present invention can be used in the preparation of constructs for use in a variety of host cells. Host for use in the present invention include, but are not limited to plant cells, bacterial cells, fungal cells (including yeast), insect cells, and mammalian cells.

For example, to confirm the activity and specificity of the proteins encoded by the 15 identified nucleic acid sequences as desaturase enzymes, *in vitro* assays can be performed in insect cell cultures using baculovirus expression systems. Such baculovirus expression systems are known in the art and are described by Lee, *et al.* U.S. Patent Number 5,348,886, the entirety of which is herein incorporated by reference.

The method of transformation in obtaining such transgenic plants is not critical to 20 the instant invention, and various methods of plant transformation are currently available. Furthermore, as newer methods become available to transform crops, they may also be directly applied hereunder. For example, many plant species naturally susceptible to *Agrobacterium* infection may be successfully transformed via tripartite or binary vector methods of *Agrobacterium* mediated transformation. In many instances, it will be 25 desirable to have the construct bordered on one or both sides by T-DNA, particularly

having the left and right borders, more particularly the right border. This is particularly useful when the construct uses *A. tumefaciens* or *A. rhizogenes* as a mode for transformation, although the T-DNA borders may find use with other modes of transformation. In addition, techniques of microinjection, DNA particle bombardment, 5 and electroporation have been developed which allow for the transformation of various monocot and dicot plant species.

Normally, included with the DNA construct will be a structural gene having the necessary regulatory regions for expression in a host and providing for selection of transformant cells. The gene may provide for resistance to a cytotoxic agent, e.g. 10 antibiotic, heavy metal, toxin, etc., complementation providing prototrophy to an auxotrophic host, viral immunity or the like. Depending upon the host species the expression construct or components thereof are introduced, one or more markers may be employed, where different conditions for selection are used for the different hosts.

Where *Agrobacterium* is used for plant cell transformation, a vector may be used 15 which may be introduced into the *Agrobacterium* host for homologous recombination with T-DNA or the Ti- or Ri-plasmid present in the *Agrobacterium* host. The Ti- or Ri-plasmid containing the T-DNA for recombination may be armed (capable of causing gall formation) or disarmed (incapable of causing gall formation), the latter being permissible, so long as the *vir* genes are present in the transformed *Agrobacterium* host. The armed 20 plasmid can give a mixture of normal plant cells and gall.

In some instances where *Agrobacterium* is used as the vehicle for transforming host plant cells, the expression or transcription construct bordered by the T-DNA border region(s) will be inserted into a broad host range vector capable of replication in *E. coli* and *Agrobacterium*, there being broad host range vectors described in the literature. 25 Commonly used is pRK2 or derivatives thereof. See, for example, Ditta, *et al.*, (*Proc.*

Nat. Acad. Sci., U.S.A. (1980) 77:7347-7351) and EPA 0 120 515, which are incorporated herein by reference. Alternatively, one may insert the sequences to be expressed in plant cells into a vector containing separate replication sequences, one of which stabilizes the vector in *E. coli*, and the other in *Agrobacterium*. See, for example, McBride and 5 Summerfelt (*Plant Mol. Biol.* (1990) 14:269-276), wherein the pRiHRI (Jouanin, *et al.*, *Mol. Gen. Genet.* (1985) 201:370-374) origin of replication is utilized and provides for added stability of the plant expression vectors in host *Agrobacterium* cells.

Included with the expression construct and the T-DNA will be one or more markers, which allow for selection of transformed *Agrobacterium* and transformed plant 10 cells. A

number of markers have been developed for use with plant cells, such as resistance to chloramphenicol, kanamycin, the aminoglycoside G418, hygromycin, or the like. The particular marker employed is not essential to this invention, one or another marker being preferred depending on the particular host and the manner of construction.

15 For transformation of plant cells using *Agrobacterium*, explants may be combined and incubated with the transformed *Agrobacterium* for sufficient time for transformation, the bacteria killed, and the plant cells cultured in an appropriate selective medium. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting 20 medium for regeneration of plants. The plants may then be grown to seed and the seed used to establish repetitive generations and for isolation of vegetable oils.

For the alteration of unsaturated fatty acid production in a host cell, a second expression construct can be used in accordance with the present invention. For example, the desaturase expression construct can be introduced into a host cell in conjunction with

a second expression construct having a nucleotide sequence for a protein involved in fatty acid biosynthesis.

There are several possible ways to obtain the plant cells of this invention which contain multiple expression constructs. Any means for producing a plant comprising a 5 construct having a DNA sequence encoding the expression construct of the present invention, and at least one other construct having another DNA sequence encoding an enzyme are encompassed by the present invention. For example, the expression construct can be used to transform a plant at the same time as the second construct either by inclusion of both expression constructs in a single transformation vector or by using 10 separate vectors, each of which express desired genes. The second construct can be introduced into a plant which has already been transformed with the desaturase expression construct, or alternatively, transformed plants, one expressing the desaturase construct and one expressing the second construct, can be crossed to bring the constructs together in the same plant.

15 The invention now being generally described, it will be more readily understood by reference to the following examples which are included for purposes of illustration only and are not intended to limit the present invention.

EXAMPLES

20

Example 1 Cloning of Desaturase Genomic Sequences

1A. Soybean Δ12 Desaturase (fad2-1)

25 The soybean fad 2-1A sequence was identified by screening a soybean genomic library using a soybean fad2-1 cDNA probe. Three putative soy fad 2-1 clones were

identified and plaque purified. Two of the three soy fad 2-1 clones were ligated into pBluescript II KS+ (Stratagene) and sequenced. Both clones (14-1 and 11-12) were the same and matched the soy fad 2-1 cDNA exactly. The sequence of the entire fad2-1A clone is provided in SEQ ID NO: 1.

5 Prior to obtaining this full length clone, a portion of the fad2-1A genomic clone was PCR amplified using PCR primers designed from the 5' untranslated sequence (Primer 12506, 5'-ATACAA GCCACTAGGCAT-3', SEQ ID NO:9) and within the cDNA (Primer 11698: 5'-GATTGGCCATGCAATGAGGGAAAAGG-3', SEQ ID NO:10. The resulting PCR product, which contained the fad2-1A intron, was cloned into 10 the vector pCR 2.1 (Invitrogen) and sequenced. The soy fad 2-1A partial genomic clone (SEQ ID NO:27) and its intron region (SEQ ID NO:2) were identified by comparison to the soybean cDNA sequence using the Pustell comparison program in Macvector. The intron sequence begins after the ATG start codon, and is 420 bases long.

A second fad2-1 gene family member was also identified and cloned, and is 15 referred to herein as fad2-1B. The soy fad 2-1B partial genomic clone (SEQ ID NO:23) (contains the promoter (base pairs 1 - 1704); 5'UTR (base pairs 1705 - 1782); intron#1 (base pairs 1786 - 2190); and a portion of the fad2-1B coding region (base pairs 1783- 1785 and 2191 - 2463)) and its intron region (SEQ ID NO:24) were identified by 20 comparison to the soybean cDNA sequence using the Pustell comparison program in Macvector. The intron sequence begins after the ATG start codon and is 405 bases long.

1B. Soybean Δ15 Desaturase (fad3)

The partial soybean fad 3 genomic sequence was PCR amplified from soybean DNA using primers 10632, 5'-

25 CUACUACUACUACTCGAGACAAAGCCTTAGCCTATG-3' (SEQ ID NO:11), and

10633: 5'-CAUCAUCAUCAUGGATCCCATGTC TCTCTATGCAAG-3' (SEQ ID NO:12). The Expand Long Template PCR system (Boehringer Mannheim) was used according to the manufacturers directions. The resulting PCR products were cloned into the vector pCR 2.1 (Invitrogen) and sequenced. The soy fad 3 partial genomic clone 5 sequence and the intron regions were confirmed by comparisons to the soybean fad 3 cDNA sequence using the Pustell program in Macvector. From the identified partial genomic soybean fad3 sequence (SEQ ID NO:3), seven introns were identified (SEQ ID NO:4 (intron #1), SEQ ID NO:5 (intron #2), SEQ ID NO:6 (intron #3A), SEQ ID NO:7 (intron #4), SEQ ID NO:8 (intron #5), SEQ ID NO:25 (intron #3B) and SEQ ID NO:26 (intron #3C)). Intron #1 is 192 base pairs long and is located between positions 294 and 485, intron #2 is 348 base pairs long and is located between positions 576 and 923, intron #3A is 142 base pairs long and is located between positions 991 and 1132, intron #3B is 98 base pairs long and is located between positions 1225 and 1322, intron #3C is 115 base pairs long and is located between positions 1509 and 1623, intron #4 is 1231 base 10 pairs long and is located between positions 1705 and 2935, and intron #5 is 626 base pairs long and is located between positions 3074 and 3699.

Example 2 Expression constructs

20 The soybean fad2-1A intron sequence was amplified via PCR using the fad2-1A partial genomic clone (SEQ ID NO:27) as a template and primers 12701 (5'-ACGAATTCTCGAGGTAAA TTAAATTGTGCCTGC-3' (SEQ ID NO:13)) and 12702 (5'-GCGAGATCTATCG ATCTGTGTCAAAGTATAAAC-3' (SEQ ID NO:14)). The resulting amplification products were cloned into the vector pCR 2.1 (Invitrogen) and 25 sequenced. The soyfad2-1A intron was then cloned into the expression cassette,

pCGN3892, in sense and antisense orientations. The vector pCGN3892 contains the soybean 7S promoter and a pea RBCS 3'. Both gene fusions were then separately ligated into pCGN9372, a vector that contains the CP4 gene regulated by the FMV promoter. The resulting expression constructs (pCGN5469 sense and pCGN5471 antisense) were used for transformation of soybean using biolistic methods described below.

5 The soybean fad2-1B intron sequence was amplified via PCR using the fad2-1B partial genomic clone (SEQ ID NO:23) as a template and primers 13883 (5'-
10 GCGATCGATGTATGATGCTAAATTAAATTGTGCCTG -3' (SEQ ID NO:30)) and 13876 (5'- GCGGAATTCCCTGTGTCAAAGTATAAAGAAG -3' (SEQ ID NO:31)). The resulting amplification products were cloned into the vector pCR 2.1 (Invitrogen) and sequenced. The soyfad2-1B intron was fused to the 3' end of the soy fad 2-1A intron in plasmids pCGN5468 (contains the soybean 7S promoter fused to the soy fad2-1A intron
15 (sense) and a pea RBCS 3') or pCGN5470 (contains the soybean 7S promoter fused to the soy fad2-1A intron (antisense) and a pea RBCS 3') in sense or antisense orientation respectively. The resulting intron combo fusions were then ligated separately into pCGN9372, a vector that contains the CP4 gene regulated by the FMV promoter. The resulting expression constructs (pCGN5485, fad2-1A&B intron sense and pCGN5486,
20 fad2-1A&B intron antisense) were used for transformation of soybean using biolistic methods described below.

25 Four of the seven introns identified from the soybean fad 3 genomic clone were PCR amplified using the soy fad 3 partial genomic clone as template and primers as follows: Intron #1, primers 12568: GATCGATGCCGGGTAATAATTTTGTGT

(SEQ ID NO:15) and 12569: CACGCCTCGAGTGTCAATTCAATCAATG (SEQ ID NO:16); Intron #2, primers 12514: 5'-CACTCGAGTTAGTTCATACTGGCT (SEQ ID NO:17) and 12515: 5'-CGCATCGATTGCAAAATCCATCAAA (SEQ ID NO:18); Intron #4, primers 10926: 5'-

5 CUACUACUACUACTCGAGCGTAAATAGTGGGTGAACAC (SEQ ID NO:19) and 10927: 5'-CAUCAUCAUCAUCTCGAGGAATTCGTCCATTAGTACACC (SEQ ID NO:20) ; Intron #5, primers 10928: 5'-CUACUACUACUACTCGAGGCGCGT ACATTATTGCTTA (SEQ ID NO:21) and 10929: 5'-CAUCAUCAUCAUCT CGAGGAATTCTGCAGTGAATCCAAATG (SEQ ID NO:22). The resulting PCR

10 products for each intron were cloned into the vector pCR 2.1 (Invitrogen) and sequenced. Introns #1, #2, #4 and #5 were all ligated separately into the, pCGN3892, in sense or antisense orientations. pCGN3892 contains the soybean 7S promoter and a pea RBCS 3'. These fusions were ligated into pCGN9372, a vector that contains the CP4 gene regulated by the FMV promoter for transformation into soybean. The resulting expression

15 constructs (pCGN5455, fad3 intron#4 intron sense; pCGN5459, fad3 intron#4 intron antisense; pCGN5456, fad3 intron#5 intron sense; pCGN5460, fad3 intron#5 intron antisense; pCGN5466, fad3 intron#2 intron antisense; pCGN5473, fad3 intron#1 intron antisense;) were used for transformation of soybean using biolistic methods described

below.

20 The soy fad3 Intron #3C and #4 were also PCR amplified from a second fad3 gene family member, herein referred to as fad3-1B. The soy fad3-1B introns #3C and #4 were PCR amplified from soybean DNA using the following primers, 5' CATGCTTCTGTGCTTCTC 3' (SEQ ID NO:32) and , 5' GTTGATCCAACCATAGTCG 3' (SEQ ID NO:33). The PCR products were cloned into

the vector pCR 2.1 (Invitrogen) and sequenced. The sequences for the soy fad3-1B introns #3C and #4 are provided in SEQ ID NOS:28 and 29.

Example 3 Plant Transformation and Analysis

5 Linear DNA fragments containing the expression constructs for sense and antisense expression of the Δ12 and Δ15 desaturase introns were stably introduced into soybean (Asgrow variety A4922) by the method of McCabe, et.al. (1988) Bio/Technology 6:923-926. Transformed soybean plants were identified by selection on media containing glyphosate.

10 Fatty acid compositions were analyzed from seed of soybean lines transformed with the intron expression constructs using gas chromatography. T2 pooled seed and T2 single seed oil compositions demonstrate that the mono and polyunsaturated fatty acid compositions were altered in the oil of seeds from transgenic soybean lines as compared to that of the seed from non-transformed soybean. Table I provides a summary
15 of results which were obtained using the described constructs. These data clearly show that sense and antisense expression of the non-coding regions of the desaturase gene results in the modification of the fatty acid compositions. The data also shows that introns can be used to obtain a variety of lines with varying fatty acid compositions. Selections can be made from such lines depending on the desired relative fatty acid
20 composition. In addition, since each of the introns is able to modify the levels of each fatty acid to varying extents, it is contemplated that combinations of introns can be used depending on the desired compositions.

TABLE I

			Oleic	Linoleic	Linolenic
Fad 2		event			
wildtype (control)		5469-5 null T2 pool 10 seed average 5469-27 null T2 pool A4922 5471-13 null T2 pool 10 seed average A4922	18.15% 13.89% 19.15% 15.75% 17.02% 13.86% 14.95%	55.59% 55.89% 54.62% 56.1% 56.49% 56.14% 55.95%	7.97% 9.067% 9.32% 8.75% 9.08% 9.49% 9.07%
full length cDNA (control)	sense	5462-133 T2 pool best 5462-133 T2 seed	84% 84%	2.17% 0.59%	1.55% 1.76%
intron 1	sense	5469-6 T2 pool 5469-8 T2 pool best 5469-6 T2 seed best 5469-8 T2 seed 5469-14 T2 pool 5469-20 T2 pool 5469-22 T2 pool best 5469-14 T2 seed 5485-3 T2 pool 5485-53 T2 pool	29.93% 36.5% 44.41% 41.26% 61.06% 48.89% 80% 62.21% 63.54% 47.58%	46.53% 42.11% 29.34% 33.16% 16.42% 31.61% 2.97% 11.97% 14.09% 27.64%	5.98% 6.68% 5.74% 7.75% 4.89% 4.78% 8.81% 7.32% 7.81%
	antisense	5471-8 T2 pool 5471-2 T2 pool 5471-26 T2 pool best 5471-8 T2 seed best 5471-2 T2 seed best 5471-26 T2 seed 5486-33 T2 pool 5486-12 T2 pool 5486-40 T2 pool	31.05% 27.98% 32.66% 57.4% 28.08% 43.3% 32.37% 27.32% 26.79%	43.62% 48.88% 44.54% 23.37% 46.14% 34.15% 43.66% 46.97% 48.72%	7.07% 6.83% 6.76% 5.73% 6.52% 5.6% 6.87% 6.4% 6.55%
Fad 3					
wildtype (control)		5473-7 null T2 pool A4922 T2 pool	15.65% 19.84%	56.74% 56.79%	9.55% 7.48%
full length cDNA (control)	sense	5464-50 T2 pool best 5464-50 T2 seed	18.06% 17.08%	62.03% 62.44%	2.75% 1.72%
intron 1	antisense	5473-8 T2 pool 5473-1 T2 pool	33.47% 33.34%	45.97% 42.67%	5.54% 7.59%
intron 2	antisense	5466-20 T2 pool 5466-16 T2 pool	28.43% 27.61%	48.83% 49.92%	6.37% 5.96%
intron 4	sense	5455-19 T2 pool 5455-10 T2 pool 5455-57 T2 pool 5455-76 T2 pool 5455-107 T2 pool best 5455-57 T2 seed best 5455-76 T2 seed best 5455-107 T2 seed	40.35% 35.14% 38.04% 37.24% 36.44% 45.36% 35.3% 45.56%	39.97% 43.59% 42.44% 42.42% 42.72% 35.55% 43.54% 34.85%	4.61% 5.53% 5.24% 5.37% 5.62% 4.92% 5.53% 5.12%
	antisense	5459-2 T2 pool 5459-6 T2 pool 5459-20 T2 pool best 5459-2 T2 seed best 5459-6 T2 seed	34.5% 33.78% 28.26% 61.45% 53.51%	43.87% 44.12% 49.48% 23.45% 29.68%	5.59% 5.62% 5.5% 3.38% 3.53%

		best 5459-20 T2 seed	30%	50.55%	4.15%
intron 5	sense	5456-38 T2 pool	28.23%	49.59%	6.74%
		5456-62 T2 pool	28.94%	48.66%	6.25%
		best 5456-62 T2 seed	29.5%	43.69%	5.4%
	antisense	5460-9 T2 pool	29.78%	48.57%	5.54%
		5460-21 T2 pool	28.37%	49.79%	5.54%
		best 5460-21 T2 seed	35.18%	40.52%	5.33%

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains.

5 All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that 10 certain changes and modifications may be practiced within the scope of the appended claims.

Claims

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
 - a) a polynucleotide comprising SEQ ID NO: 1;
 - 5 b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 1 over the entire length of SEQ ID NO: 1;
 - c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 1 over the entire length of SEQ ID NO: 1;
 - d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 1 over the entire length of SEQ ID NO: 1;
 - 10 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 1 over the entire length of SEQ ID NO: 1;
 - f) a polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 1 or a fragment thereof; and
 - 15 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

2. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 2;
- 20 b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 2 over the entire length of SEQ ID NO: 2;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 2 over the entire length of SEQ ID NO: 2;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 2 over the entire length of SEQ ID NO: 2;

- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 2 over the entire length of SEQ ID NO: 2;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 2 or a fragment thereof; and
- 5 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

3. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 3;
- 10 b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 3 over the entire length of SEQ ID NO: 3;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 3 over the entire length of SEQ ID NO: 3;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 3
- 15 over the entire length of SEQ ID NO: 3;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 3 over the entire length of SEQ ID NO: 3;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 3 or a fragment thereof; and
- 20 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

4. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 4;

- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 4 over the entire length of SEQ ID NO: 4;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 4 over the entire length of SEQ ID NO: 4;
- 5 d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 4 over the entire length of SEQ ID NO: 4;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 4 over the entire length of SEQ ID NO: 4;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID 10 NO: 4 or a fragment thereof; and
- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

5. An isolated polynucleotide selected from the group consisting of:

- 15 a) a polynucleotide comprising SEQ ID NO: 5;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 5 over the entire length of SEQ ID NO: 5;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 5 over the entire length of SEQ ID NO: 5;
- 20 d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 5 over the entire length of SEQ ID NO: 5;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 5 over the entire length of SEQ ID NO: 5;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID 25 NO: 5 or a fragment thereof; and

g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

6. An isolated polynucleotide selected from the group consisting of:

5 a) a polynucleotide comprising SEQ ID NO: 6;

b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;

c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;

10 d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;

e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 6 over the entire length of SEQ ID NO: 6;

f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID 15 NO: 6 or a fragment thereof; and

g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

7. An isolated polynucleotide selected from the group consisting of:

20 a) a polynucleotide comprising SEQ ID NO: 7;

b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 7 over the entire length of SEQ ID NO: 7;

c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 7 over the entire length of SEQ ID NO: 7;

- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 7 over the entire length of SEQ ID NO: 7;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 7 over the entire length of SEQ ID NO: 7;
- 5 f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 7 or a fragment thereof; and
- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

10 8. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 8;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 8 over the entire length of SEQ ID NO: 8;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 8 over the entire length of SEQ ID NO: 8;
- 15 d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 8 over the entire length of SEQ ID NO: 8;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 8 over the entire length of SEQ ID NO: 8;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 8 or a fragment thereof; and
- 20 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

9. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 23;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- 5 c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- 10 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 23 over the entire length of SEQ ID NO: 23;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 23 or a fragment thereof; and
- 15 g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

15

10. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 24;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;
- 20 c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;
- 25 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 24 over the entire length of SEQ ID NO: 24;

- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 24 or a fragment thereof; and
- g) a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

5

11. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 25;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 25 over the entire length of SEQ ID NO: 25;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 25 or a fragment thereof; and
- a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

15

12. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 26;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 26 over the entire length of SEQ ID NO: 26;

20

- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 26 over the entire length of SEQ ID NO: 26;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 26 over the entire length of SEQ ID NO: 26;
- 5 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 26 over the entire length of SEQ ID NO: 26;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 26 or a fragment thereof; and a polynucleotide sequence complementary to the polynucleotide sequence of (a),

10 (b), (c), (d), (e), or (f).

13. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 27;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 27 over the entire length of SEQ ID NO: 27;
- 15 c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 27 over the entire length of SEQ ID NO: 27;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 27 over the entire length of SEQ ID NO: 27;
- 20 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 27 over the entire length of SEQ ID NO: 27;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 27 or a fragment thereof; and a polynucleotide sequence complementary to the polynucleotide sequence of (a),

25 (b), (c), (d), (e), or (f).

14. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 28;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 28
5 over the entire length of SEQ ID NO: 28;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 28
over the entire length of SEQ ID NO: 28;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 28
over the entire length of SEQ ID NO: 28;
- 10 e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 28
over the entire length of SEQ ID NO: 28;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID
NO: 28 or a fragment thereof; and
a polynucleotide sequence complementary to the polynucleotide sequence of (a),
15 (b), (c), (d), (e), or (f).

15. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising SEQ ID NO: 29;
- b) a polynucleotide sequence having at least 70% identity to that of SEQ ID NO: 29
20 over the entire length of SEQ ID NO: 29;
- c) a polynucleotide sequence having at least 80% identity to that of SEQ ID NO: 29
over the entire length of SEQ ID NO: 29;
- d) a polynucleotide sequence having at least 90% identity to that of SEQ ID NO: 29
over the entire length of SEQ ID NO: 29;

- e) a polynucleotide sequence having at least 95% identity to that of SEQ ID NO: 29 over the entire length of SEQ ID NO: 29;
- f) an polynucleotide sequence that hybridizes, under stringent conditions, to SEQ ID NO: 29 or a fragment thereof; and

5 a polynucleotide sequence complementary to the polynucleotide sequence of (a), (b), (c), (d), (e), or (f).

16. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

- 10 a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1;
- b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1;
- c) a genomic polynucleotide sequence having at least 90% identity to coding

15 regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1; and

- d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO: 1 over the entire coding regions of SEQ ID NO:1.

17. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

- 20 a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3;
- b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3;

- c) a genomic polynucleotide sequence having at least 90% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3; and
- d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO: 3 over the entire coding regions of SEQ ID NO:3.

5

18. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

- a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23;
- b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23;
- c) a genomic polynucleotide sequence having at least 90% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23; and
- d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO:23 over the entire coding regions of SEQ ID NO:23.

19. An intron obtained from a genomic polynucleotide sequence selected from the group consisting of:

- a) a genomic polynucleotide sequence having at least 70% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27;
- b) a genomic polynucleotide sequence having at least 80% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27;
- c) a genomic polynucleotide sequence having at least 90% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27; and

d) a genomic polynucleotide sequence having at least 95% identity to coding regions of SEQ ID NO:27 over the entire coding regions of SEQ ID NO:27.

20. A recombinant DNA construct comprising at least one of the
5 polynucleotide sequences of Claims 1-19.

21. The recombinant DNA construct according to Claim 20, wherein said polynucleotide sequence is an intron sequence.

10 22. The recombinant DNA construct according to Claim 21, wherein said intron sequence is in an orientation selected from the group consisting of sense and antisense.

23. A plant cell comprising the DNA construct of 20.

15

24. A plant comprising the cell of Claim 24.

25. A method of modifying the fatty acid composition in a plant cell, said method comprising:

20 transforming a plant cell with the construct of Claim 21 and,
growing said cell under conditions wherein transcription of said polynucleotide sequence is initiated,
whereby said fatty acid composition of said cell is modified.

26. The method according to Claim 25, wherein said modification is selected from the group consisting of an increase in oleic acid, a decrease in linolenic acid and a decrease in linoleic acid.

5 27. The method according to Claim 25, wherein said polynucleotide sequence is an intron sequence.

28. The method according to Claim 27, wherein said intron sequence is in an orientation selected from the group consisting of sense and antisense.

10

29. A plant cell produced by the method of claim 25.

30. A method of inhibiting gene expression in a plant cell, comprising the steps of: transforming a plant cell with a DNA construct comprising a non-coding region of a gene to 15 be inhibited positioned in a sense orientation; and growing said cell under conditions wherein transcription of said non-coding region is initiated, whereby said expression of said gene is inhibited.

31. The method according to claim 30 wherein said non-coding region is selected from 20 the group consisting of an intron, a promoter region, a 5' untranslated region and portions of such sequences.

32. The method according to claim 30 wherein said non-coding region is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:24, SEQ ID NO:4, SEQ ID NO:5, SEQ ID

NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:29.

33. The method according to claim 30 wherein said gene encodes desaturase.

5

34. A method of inhibiting desaturase expression in a plant cell, comprising the steps of: transforming a plant cell with a DNA construct comprising a non-coding region of a gene encoding desaturase positioned in an antisense orientation; and growing said cell under conditions wherein transcription of said non-coding region is initiated, whereby said expression of said desaturase is inhibited.

10

35. The method according to claim 34 wherein said non-coding region is selected from the group consisting of an intron, a promoter region, a 5' untranslated region and portions of such sequences.

15

36. The method according to claim 34 wherein said non-coding region is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:24, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:29.

20

37. A plant cell produced according to the method of claim 34.

25

38. The plant cell according to claim 37 wherein said cell includes an oil composition comprising at least about 80 - 85% oleic acid, no more than about 1 - 2% linoleic acid and no more than about 1-3% linolenic acid.

39. The plant cell according to claim 37 wherein said cell includes an oil composition comprising at least about 50 - 75% oleic acid, no more than about 10 - 30% linoleic acid and no more than about 1-3% linolenic acid.

5

40. A method of modifying fatty acid composition in a plant cell, comprising the steps of:

transforming a plant cell with a DNA construct comprising a non-coding region of a gene encoding desaturase positioned in a sense or an antisense orientation; and

10 growing said cell under conditions wherein transcription of said non-coding region is initiated, whereby said expression of said desaturase is inhibited.

15 41. The method according to claim 40 wherein said non-coding region is selected from the group consisting of an intron, a promoter region, a 5' untranslated region and portions of such sequences.

20 42. The method according to claim 41 wherein said non-coding region is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:24, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:29.

43. A plant cell produced according to the method of claim 40.

44. The plant cell according to claim 43 wherein said cell includes an oil composition comprising at least about 80 - 85% oleic acid, no more than about 1 - 2% linoleic acid and no more than about 1-3% linolenic acid.

5 45. The plant cell according to claim 43 wherein said cell includes an oil composition comprising at least about 50 - 75% oleic acid, no more than about 10 - 30% linoleic acid and no more than about 1-3% linolenic acid.

10 46. A method of inhibiting desaturase expression in a plant cell, comprising the steps of: transforming a plant cell with a DNA construct comprising a nucleic acid sequence capable of binding to or cleaving a non-coding region of a gene encoding desaturase; and growing said cell under conditions wherein transcription of said nucleic acid sequence is initiated, whereby said expression of said desaturase is inhibited.

15 47. A plant cell produced according to the method of claim 46.

20 48. A oil seed composition comprising:
at least about 50 - 75% oleic acid, no more than about 10 - 30% linoleic acid and no more than about 1-3% linolenic acid.

SEQUENCE LISTING

<110> Fillatti, Joanne J.

<120> Nucleic Acid Sequences and Methods of Use for the Production of Plants with Modified Polyunsaturated Fatty Acids

<130> 17138/00/WO

<140> new application
<141> 2000-08-11

<150> 60/151,224
<151> 1999-08-26

<150> 60/172,128
<151> 1999-12-17

<160> 33

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 4497

<212> DNA
<213> Glycine max

<400> 1

cttgcttgg	aacaacgtcg	tcaagttatt	atttgttct	ttttttttt	atcatatttc	60
tttattttgtt	ccaagtatgt	catatttga	tccatcttga	caagtagatt	gtcatgttagg	120
aataggaata	tcactttaaa	ttttaaagca	ttgattagtc	tgtaggaat	attgtcttct	180
tcttcctcct	tattaatatt	tttattctg	ccttcaatca	ccagttatgg	gagatggatg	240
taaactaaa	taccatagtt	gttctgttg	aagtttagtt	gtatagttgt	tctgcttga	300
gttttagttgt	gtgtatgtt	tcagcgttgg	cttcccctgt	aactgcatac	atggtaactga	360
atatatattt	tttgattgt	tcattttttt	ctttactta	atcttcattt	cttggaaatt	420
aataaaaacaa	aaagaaggac	cgaatagttt	gaagttgaa	ctattgccta	ttcatgtaac	480
ttttccccc	aatcttattt	agttttctg	gtagagatca	tttaaattt	aaggatataa	540
attaagggaa	aatacttgta	tgtgatgtgt	ggcaattttgg	aagatcatgc	gtagagagtt	600
taatggcagg	tttgcaaat	tgacctgtag	tcaatttttca	actggggccct	ctcggagttt	660
tgtgcctttt	tgttgcgtct	gtgtttgtt	ctgcattgtt	gcctcacaca	gatatttttagt	720
agttgtgtt	ctgcataataa	gcctcacacg	tatactaaac	gagtgaacct	caaattatcg	780
gccttacacc	tattgagtga	aattaatgaa	cagtgcattgt	gagtagttgt	ctgtgacacaca	840
accccccgtt	ttcatattgc	aatgtgtac	tgtgggtatt	aaccttgcta	cactgtcgtc	900
cttggttgtt	tccttatgtt	tattgatacc	ataaattatt	actagtata	cattttata	960
tgtccatacc	attacgtgtt	tatagtctt	ttatgacatg	taattgaatt	tttaaattt	1020
aaaaaaataat	aaaacttaat	tacgtactat	aaagagatgc	tcttgactag	aattgtgtac	1080
tccttagttt	ctaacccat	actaatattt	gtttgtattt	atagccccc	cgttcccaag	1140
agtataaaaac	tgcattgtat	aatacaagcc	actaggcatg	gtaaaattaaa	tttgtgcctgc	1200
acctcgggat	atttcatgtt	gggttcatca	tattgttga	ggaaaagaaa	ctcccgaaat	1260
tgaattatgtc	atttatatat	ccttttcat	ttttagattt	cctgaaggct	taggtgttagg	1320
caccttagcta	gtagctacaa	tatcagca	tcttcttatt	gataaaacat	tggctgttaat	1380
gcccgagtag	aggacgtatca	caacatttcg	tgttggttac	ttttttgtttt	atggtcatga	1440
tttcactctc	tctaattctt	ccattcattt	tgtatgttgc	attatcttta	gatttttcac	1500

tacctggttt	aaaattgagg	gattgttagtt	ctgttggtag	atattacaca	ttcagcaaaa	1560
caactgaaac	tcaactgaac	ttgttatac	tttgacacag	ggtctagcaa	aggaacaac	1620
aatggggaggt	agaggtcgt	tggcaaagt	gaagttcaag	ggaagaagcc	tctctcaagg	1680
gttccaaaca	caaagccacc	attcactgtt	ggccaaactca	agaaaagcaat	tccaccacac	1740
tgcttcage	gctccctcct	cacttcattt	tcctatgtt	tttatgacct	ttcatggcc	1800
ttcattttct	acattgccac	cacctacttc	caccccttc	ctcaaccctt	ttccctcatt	1860
gcattggccaa	tctattgggt	tctccaaggt	tgccttctca	ctgggtgtgt	ggtgattgct	1920
cacgagtgt	gtcaccatgc	cttcagcaag	taccaatggg	ttgtatgtgt	tgtggggttg	1980
acccttcaact	caacactttt	agtcccttat	ttctcatgga	aaataagcca	tcgcccctat	2040
cactccaaca	caggtttccct	tgaccgtgat	gaagtgttt	tccaaaacc	aaaatccaaa	2100
gttgcattgtt	tttccaagta	ctaaacaaac	cctcttaggaa	gggctgtttc	tcttcgtc	2160
acactcacaa	tagggggcc	tatgttta	gccttcaatgt	tctctgttag	accctatgt	2220
agtttgcaaa	gccactacca	ccctttagct	cccatatattt	ctaacccgtga	gaggctctg	2280
atctatgtct	ctgatgttgc	tttgcattct	gtgacttact	cctcttaccg	tgttgcacc	2340
ctgaaaagggt	tgggttggct	gctatgtgtt	tatgggttgc	cttgcgtcat	tgtgaacgg	2400
tttcttgcata	ctatcacata	tttgcagcac	acacactttt	ccttgcctca	ttacgattca	2460
tcagaatggg	actggctgaa	ggggagtttt	gcaactatgg	acagagatta	tgggattctg	2520
aacaagggtt	ttcatcacat	aactgatact	catgtggctc	accatcttct	ctctacaatg	2580
ccacattacc	atgcaatgga	ggcaaccaat	gcaatcaagc	caatattggg	tgagtactac	2640
caattttgat	acacaccatt	ttacaaggca	ctgtggagag	aagcgagaga	gtgcctctat	2700
gtggagccag	atgaaggaac	atccgagaaag	ggcgtgtt	ggtacagggaa	caagtattga	2760
tggagcaacc	aatggggccat	agtggggagtt	atggaaagt	tgtcatgtat	tagtacataa	2820
tttagtagaaat	gttataataa	agtggatttt	ccgcgtaatg	actttgtgt	tatttgaaa	2880
cagcttgg	cgatcatgtt	tataatgtaa	aaataattt	ggtattaaat	acatgtggaa	2940
agtttctgc	ttatagctt	ctgcctaaaa	tgcacgctgc	acgggacaat	atatttggta	3000
attttttaa	aatctgaatt	gaggctactc	ataataactat	ccataggaca	tcaaagacat	3060
gttgcattga	ctttaaagcag	aggttcatct	agaggattac	tgcataaggct	tgaactacaa	3120
gtaatttaaag	ggacgagagc	aacttttagct	ctaccacgtc	gttttacaag	gttattaaaa	3180
tcaaattgt	cttattaaaa	ctgaaaattt	gtaataaaat	gctattgaaa	aattaaaata	3240
tagcaaacac	ctaaatttga	ctgatttttta	gattcaaatt	taataattaa	tctaaattaa	3300
actttattt	tataatataat	gtcttgcata	atatacgat	ttttttttt	ttatttgagtt	3360
ttgaaaacata	taataaggaa	cattgtttaa	tattgataat	ccactaaagat	cgacttagta	3420
ttcagttttt	tggatgattt	gtatggatata	ttcaacttcc	acttttatca	taatagagac	3480
aaaagttaat	actgtatgtt	gagaaaaaaa	aatgttattt	ggagcatatgc	gtaagataag	3540
acggataaaaa	atatgtcga	gcctggagag	ctaatgtatt	ttttggtcaa	gtttcaagt	3600
gacaactatt	catgtgaga	acacaataat	attttctact	tacctatccc	acataaaaata	3660
ctgattttaa	taatgtatgt	aaataatgtat	taaaatattt	gattttttgt	taagagaaat	3720
aaggaaaaca	taaatattct	catggaaaaaa	tcagcttgc	ggagtagaaa	ctttctgatt	3780
ataattttaa	tcaagttaa	ttcatttttt	taattttattt	attagtacaa	aatcattctc	3840
ttgaattttag	agatgtatgt	tgttagcttaa	tagtaatttt	ttatttttat	aataaaaattc	3900
aaggcgtcaa	atttcatcca	aataatcgta	ttcgtgggt	taagtcaattt	attccttctt	3960
atcttaataat	acacgcaaaag	gaaaaaataaa	aaataaaattt	cgaggaagcg	cagcagcagc	4020
tgataccacg	ttgggtgacg	aaactgataaa	aaagcgctgt	cattgtgtct	ttgtttgatc	4080
atcttcacaa	tcacatctcc	agaacacaaa	gaagagtgc	ctttcttctt	tttattccac	4140
ttgcgtttagg	tttctacttt	tttctctctc	tcttcttctc	tcttcattcc	tcattttcc	4200
ctcaaacaat	caatcaattt	tcatttcagat	tcgttaattt	ctcgattaga	tcacggggtt	4260
aggcttccca	ctttatcttt	tcccaagctt	ttctcttcc	ccctttccct	gtctgccccca	4320
taaaatttcag	gatcgaaac	gaactgggtt	cttgaatttc	actctagatt	ttgacaaatt	4380
cgaagtgtgc	atgcactgt	gcgaccctact	cccccttttt	tgcatcaaac	aattatgaat	4440
tgagggtttt	tttgcgtatca	tcatttgctt	aattgaatca	tattaggttt	agatttt	4497

<210> 2
 <211> 420
 <212> DNA
 <213> Glycine max

<400> 2

gtaaaattaaa	ttgtgcctgc	acctcggtat	atttcatgtg	gggttcatca	tatttgttga	60
ggaaaagaaa	ctcccgaaat	tgaattatgc	atttatatat	cccttttcat	ttcttagatt	120
cctgaaggct	taggtgtagg	cacctagcta	gtagctacaa	tatcagca	tctcttatt	180
gataaacaat	tggctgtat	gcccgcgttag	aggacatca	caacatccg	tgctggttac	240
tttttgggtt	atggtcatga	tttcaactctc	tctaattctc	ccattcattt	tgtagttgtc	300
attatctta	gattttcac	tacctgggtt	aaaattgagg	gattgttagt	ctgttggta	360
atattacaca	ttcagcaaaa	caactgaaac	tcaactgaac	ttgttatac	tttgacacag	420

<210> 3

<211> 4010

<212> DNA

<213> Glycine max

<400> 3

acaaaaggcctt	tagccttatgc	tgccaataat	ggataccaaac	aaaagggttc	ttcttttgat	60
tttgatccta	gcccgcctcc	accgtttaag	attgcagaaa	tcaagatcc	aataccaaaa	120
cattgtctgg	tcaagaatcc	atggagatcc	ctcaggatag	tttcaggga	tgtgcttga	180
attgctgcat	tggctgtgc	agcaattcac	ttcgacaaact	ggcttctctg	gctaattctat	240
tgccccatcc	aaggcacaat	gttctgggtc	ctctttgttc	ttggacatga	ttggtaataaa	300
tttttgggtt	tcttactctt	ttttttttt	ttttgtttat	gatatgaatc	tcacacattt	360
ttctgtttagt	tcatttcttc	ttcatttggc	tttagacaaac	ttaaatttga	gatcttattt	420
atgttttgc	ttatatggta	aagtgattct	tcatttattt	attcttctt	gattgaattt	480
aacagtggcc	atggaagctt	ttcagatgc	cctttgtga	atagcctgg	gggacacatc	540
ttgcatttcc	caatttctgt	gccataccat	ggatggtag	ttcatactgg	ctttttgtt	600
tgttcatttt	tcatttggaa	aaaatctttt	gttgattcaa	ttatttttat	agtgtgttt	660
gaagcccggtt	tgagaaaata	agaaatcgca	tctggatgt	gaaagtattt	actatttagc	720
ttcatctgtc	tttgcaggat	cttttattgg	ttaaattttt	atagcgtgt	agggaaaccca	780
ttcgagaaaa	taagaaatca	catctggat	gtgaaagttt	taactgttag	cttctgagta	840
aacgtggaaa	aaccacattt	ttgatttgg	accaaattttt	atttgataaa	tgacaaccaa	900
attgattttt	atggattttt	caggagaattt	agccacagaa	ctcaccatga	aaaccatgga	960
cacattgaga	aggatgagtc	atgggttcca	gtatgtgatt	aattgttct	cctatagttg	1020
ttcttgattt	aattacattt	tatttattt	gtaggtccaa	aaaaaaagg	aatctttagt	1080
cttcctgagg	ctgttcttgc	acatggctct	tttttatgt	tcattatctt	agttacacaga	1140
gaagatttac	aagaatctag	acagcatgac	aagacttatt	agattca	tgcattttcc	1200
atgtttgtgt	atccaaattt	tttgggtgat	gatttttga	tttggaaagac	aacaacacat	1260
tatttattt	atatgtttca	aaacaatgac	tttttcttta	tgatgtgaac	tccatttttt	1320
atgtttcaag	aagccccgg	aaggaaggct	ctcacttcaa	tccctacagc	aatcttgc	1380
cacccagtga	gagaaaagga	atagcaat	caacactgt	ttgggctacc	atgtttctc	1440
tgcttatcta	tctcttattt	atttactgt	ccacttctt	tgctcaagct	ctatgaaatt	1500
ccatatttgg	taacttattt	actccttacat	tgttactttt	tcctcccttt	tttttatttt	1560
tcaatttctcc	aatttggaaat	tttggaaatgt	taccataatt	atgttattt	tttgcattgt	1620
gcagatgttt	gttatgtggc	ttgactttgt	cacatactt	catcaccat	gtcaccacca	1680
gaaaactgcct	ttgttaccgcg	gcaaggtaac	aaaaataaaat	agaaaatagt	gggtgaacac	1740
ttaaatgcga	gatagaata	cctaaaaaaa	aaaaaaaata	taggtataat	aaataatata	1800
actttcaaaa	taaaaagaaa	tcatagatgc	tagcgatgt	tttggagtga	aatgtatgtc	1860
accttaccat	actcaaaat	tttgggtgt	ccctttagtt	atttttattt	ttttacat	1920
cttacttggaa	aagactttt	aattttcat	tgagatctt	aagtgtactgt	taaatttttt	1980
taaaaaacaa	gtttgtttaa	acttcaaata	aataaagat	agggaggt	cattttgttt	2040
ctttcttttta	ttgcgttatt	aatcacgtt	ctttttttt	ttttttttt	tttctctgt	2100
ttccacccat	tatcaagtcc	atgtgaagca	gtggcggatc	tatgtaaatg	agtggggggc	2160
aatttgcaccc	acaagatttt	atttttattt	tgtacaggaa	taataaaaata	aaactttgcc	2220
cccatataaaa	ataaaatattt	tttcttttttta	taatgcaaaa	taaataataag	aaataaaaaag	2280
agaataaaattt	attttaattt	gtacttttttta	tttagttttt	ttagcggtt		2340

gatttttttt	tcatgacatt	atgtaatctt	ttaaaaagcat	gtaatatttt	tatTTTGTGA	2400
aaataaaat	aatatgatcat	attagtctca	gaatgtataa	actaataata	atTTTATCAC	2460
taaaaagaaat	tctaatttag	tccataaata	agtaaaaacaa	gtgacaatta	tatTTTATAT	2520
ttacttaatg	tgaaataata	cttgaacatt	ataataaaaac	ttaatgacag	gagatattac	2580
atagtgccat	aaagatattt	taaaaaataa	aatcattaat	acactgtact	actatataat	2640
attcgatata	tatTTTtaac	atgattctca	atagaaaaat	tgtattgatt	atatTTTATT	2700
agacatgaat	ttacaagccc	cgttttcat	ttatagctct	tacctgtgat	ctattgttt	2760
gcttcgctgt	ttttgttgg	caagggactt	agatgtcaca	atattaatac	tagaagtaaa	2820
tatTTTatgaa	aacatgtacc	ttacctcaac	aaagaaaagt	tggtaagtgg	caacacacgt	2880
gttgcattt	tggcccagca	ataacacgtg	ttttgttgg	gtactaaaat	ggacaggaat	2940
ggagtattt	aagaggtggc	ctcaccactg	tggatcgtga	ctatggttgg	atcaataaca	3000
ttcaccatga	cattggcacc	catgttattcc	accatTTTT	cccccaattt	cctcattatc	3060
acctcggtga	agcggtacat	tttattgctt	attcacctaa	aaacaataaca	attagtagat	3120
ttgttttattc	tcttggaaagt	tagtcatTTT	cagttgcattg	attctaattgc	tctctccatt	3180
cttaaatcat	gttttcacac	ccacttcatt	taaaaataaga	acgtgggtgt	tatTTTattt	3240
tctattcact	aacatgagaa	attaacttat	ttcaagtaat	aatTTTaaa	tatTTTATG	3300
ctattatTTT	attacaaata	attatgtata	ttaagtttat	tgatTTTata	ataattatata	3360
taaaaattata	tcgatattaa	tttttatttc	actgatagt	ttttatattt	tttagtactgt	3420
gcatttattt	taaaaattggc	ataaaataata	tatgtacca	gctcactata	ctataactggg	3480
agcttggtgg	tgaaaggggt	tcccaaccct	cctttctagg	tgtacatgt	ttgataacttc	3540
tggtaccttc	ttatataat	ataaaattata	ttttgttggat	aaaaaaacat	ggtaaccat	3600
taaattttttt	ttttaaaaaa	aaaactgtat	ctaaactttt	tattttaaa	aagaagtctg	3660
agattaacaa	taaactaaca	ctcattttgg	ttcactgcag	acacaaggcag	caaaaccagt	3720
tcttggagat	tactaccgtg	agccagaaaag	atctgcgc	ttaccatttc	atctaataaa	3780
gtatTTTattt	cagagtatga	gacaagacca	cttcgtaaat	gacactggag	atgttggta	3840
ttatcagact	gattctctgc	tcctccactc	gcaacgagac	ttagttcaa	actTTTggg	3900
ttattatTTT	ttgattcttag	ctactcaat	tactttttt	ttaatgttat	gtttttgg	3960
gttttaacgtt	ttctgaacaa	cttgcattt	acttgcata	agagacatgg		4010

<210> 4
<211> 192
<212> DNA
<213> Glycine max

<400> 4						
gtaataattt	ttgtgtttct	tactctttt	ttttttttt	tgtttatgtat	atgaatctca	60
cacattgttc	tgttatgtca	tttcttcttc	atttggcttt	agacaactta	aatttgagat	120
cttttattatg	tttttgccta	tatggtaaag	tgattctca	ttatTCattt	cttcattgtat	180
tgaattgaac	ag					192

<210> 5
<211> 348
<212> DNA
<213> Glycine max

<400> 5						
gttagttcat	actggctttt	ttgtttgttc	atttgcattt	gaaaaaaaaat	cttttggta	60
ttcaattatt	tttataatgt	gtttggaaagc	ccgttgaga	aaataagaaa	tcgcattctgg	120
aatgtgaaag	ttataactat	ttagcttcat	ctgtcggtgc	agttttttt	attggtaaaa	180
tttttataagc	gtgcttaggaa	accattcga	gaaaataaga	aatcacatct	ggaatgtgaa	240
agttataact	gttagcttct	gagtaaacgt	ggaaaaacca	cattttggat	ttggaaccaa	300
atTTTatttt	ataaaatgaca	accaaattga	ttttgatgga	tttgcag		348

<210> 6
<211> 142

<212> DNA
<213> Glycine max

```
<400> 6
gtatgtgatt aattgcttct cctatagttg ttcttgattc aattacattt tatttatttg      60
gtaggtccaa gaaaaaaaggg aatctttatg cttccctgagg ctgttcttga acatggctct 120
tttttatgtq tcatttatctt aq                                              142
```

<210> 7
<211> 1231
<212> DNA
<213> Glyc

<210> 8
<211> 626
<212> DNA
<213> Glycine max

<210> 9

<211> 18
<212> DNA
<213> Synthetic Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 9
ataacaagccca ctaggcat 18

<210> 10
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 10
gattggccat gcaatgaggg aaaaagg 26

<210> 11
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 11
cuacuacuac uactcgagac aaagccttta gcctatg 37

<210> 12
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 12
caucaucauc auggatccca tgtctctcta tgcaag 36

<210> 13
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

<400> 13
acgaattcct cgaggtaaat taaattgtgc ctgc 34

<210> 14

<211> 33	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Oligonucleotide	
<400> 14	
gcgagatcta tcgatctgtg tcaaagtata aac	33
<210> 15	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Oligonucleotide	
<400> 15	
gatcgatgcc cgggtaata attttgtgt	30
<210> 16	
<211> 29	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Oligonucleotide	
<400> 16	
cacgcctcga gtgttcaatt caatcaatg	29
<210> 17	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Oligonucleotide	
<400> 17	
cactcgagtt agttcataact ggct	24
<210> 18	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Oligonucleotide	
<400> 18	
cgcatcgatt gcaaaatcca tcaaa	25
<210> 19	

<211> 38		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic Oligonucleotide		
<400> 19		
cuacuacuac uactcgagcg taaatagtgg gtgaacac		38
<210> 20		
<211> 41		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic Oligonucleotide		
<400> 20		
caucaucauc auctcgagga attcgtccat tttagtagtacac c		41
<210> 21		
<211> 39		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic Oligonucleotide		
<400> 21		
cuacuacuac uactcgaggc gcgtacattt tattgctta		39
<210> 22		
<211> 41		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic Oligonucleotide		
<400> 22		
caucaucauc auctcgagga attctgcagt gaatccaaat g		41
<210> 23		
<211> 1734		
<212> DNA		
<213> Glycine max		
<400> 23		
actatagggc acgcgtggc gacggcccg gctggtcctc ggtgtgactc agccccaaat	60	
gacgccaacc aaacgcgtcc taactaagggt gtagaaagaaa cagatagtat ataagtataac	120	
catataagag gagagtggagt ggagaagcac ttctcctttt tttttctctg ttgaaattga	180	
aagtgttttc cggaaataaa ataaaataaa ttaaaatctt acacactcta ggttaggtact	240	
tctaatttaa tccacacttt gactctatat atgttttaaa aataattata atgcgtactt	300	
acttcctcat tataactaaat ttaacatcga tgattttatt ttctgtttct cttctttcca	360	

cctacataca	tcccaaatt	tagggtgcaa	tttaagttt	attaacacat	gttttagct	420
gcacatgtgc	tttgcgtgt	ctcaccaat	tgcattctc	tctttatgt	ttgtatttga	480
atttcacac	cataatgtaaa	caagattacg	tacgtgtcca	tgatcaaata	caaatgctgt	540
cttatactgg	caatggata	aacagccgtc	catttttct	tttctcttt	aactatata	600
gctctagaat	ctctgaagat	tcctctgcca	tcgaatttct	ttcttggtaa	caacgtcg	660
gttatgttat	tattttattt	tatcatata	tattttctt	tttgcgtgaa	720	
gtatgtcata	ttttgatcg	gacaattaga	ttgtcatgt	ggagtaggaa	tatcactta	780
aaacattgtat	tagtctgtag	gcaatattgt	cttcttttc	ctcccttatt	aatatattt	840
gtcgaagttt	taccacaagg	ttgattcgct	ttttttgtcc	cttctcttg	ttcttttac	900
ctcaggattt	ttagtcttc	atggattata	agatcactga	gaagtgtatg	catgtaaatac	960
taagcaccat	agctgttctg	cttgaatttta	tttgcgtgt	aattgtatgt	tttcagcg	1020
ggctttccct	gtatgtgc	caatggtaact	gtatatctat	ttttgcattt	gttttcattt	1080
tttcttttac	ttaatcttca	ttgccttggaa	attaataaaa	caatataata	tagtttgaac	1140
tttgaactat	tgcctattca	tgtatattaa	ttatttactg	actcttattt	ttttctggt	1200
agaatttattat	ttaaatttggaa	ggataaaatta	agaggcaata	cttgcataattt	gacctgtcat	1260
aatttacacag	gaccctgttt	tgtgcctttt	tgtctgtc	tttgcgtttt	catgttagcc	1320
tcacacagat	atttatgtat	tgtctgtcat	acaaggctca	cacgtataact	aaaccagtgg	1380
acctcaaagt	catggcctta	cacatttgc	atgcgagtct	gtgacacaac	ccctggttc	1440
catattgcaa	tgtgcgtacgc	cgtcgccctt	gtttgttcc	atatgtatata	tgtatccatc	1500
aaatttattat	atcatttata	ttgtctggac	cattacgtgt	actcttattt	acatgtaaatt	1560
gagttttta	ataaaaaaa	tcaatgaaat	ttaactacgt	agcatcatat	agagataatt	1620
gactagaaat	ttgatgactt	attcttcc	aatcatattt	tcttgcattt	atagccccgc	1680
tgtccctttt	aaactcccga	gagagtataa	aactgcac	aatattacaa	gatg	1734

<210> 24

<211> 405

<212> DNA

<213> Glycine max

<400> 24

gtatgtatgt	aaataaaattt	gtgcctgcac	cccaggat	ttcatgtggg	attcatcatt	60
tattgagggaa	aactctccaa	attgaatcg	gcatttat	ttttttccaa	tttcttagatt	120
tcttgaaggc	ttatggtata	ggcacctaca	attatcagca	cttctctcta	ttgataaaaca	180
atggctgtat	ataccacagt	agagaacgat	cacaacattt	tgtgcgtgtt	acctttgtt	240
ttatggctat	gatttctactc	tctctaatct	gtcacttccc	tccatttattt	ttgtacttct	300
catatttttc	acttcctgg	tggaaattgt	agttcttctt	gtacatacta	gtatttagaca	360
ttcagcaaca	acaactgaac	tgaacttctt	tatacttga	cacag		405

<210> 25

<211> 98

<212> DNA

<213> Glycine max

<400> 25

gtgagtgatt	ttttgacttg	gaagacaaca	acacatttt	attataat	ggttcaaaac	60
aatgactttt	tctttatgt	gtgaactcca	tttttttt			98

<210> 26

<211> 115

<212> DNA

<213> Glycine max

<400> 26

gtaactaaat	tactcctaca	ttgttacttt	ttcctcc	tttttattat	ttcaattctc	60
caattggaaa	tttggaaatag	ttaccataat	tatgtattt	tttgcatttgc		115

<210> 27
 <211> 778
 <212> DNA
 <213> Glycine max

<220>
 <221> misc_feature
 <222> (1)...(778)
 <223> n = A,T,C or G

<400> 27

atacaagcca	ctaggcatgg	taaattaaat	tgtgcctgca	cctcgggata	tttcatgtgg	60
ggttcatcat	atttgtttag	aaaaagaaaac	tcccgaaatt	gaattatgca	tttatataatc	120
cttttcatt	tctagatttc	ctgaaggctt	aggtgttaggc	accttagctag	tagctacaat	180
atcagcactt	ctctctattt	ataaaacaatt	ggctgtaatg	ccgcagtaga	ggacgatcac	240
aacatttcgt	gctgggtact	ttttgttta	tggcatgtat	ttcaactctct	ctaatctctc	300
cattcattt	gtatgttca	ttatcttag	attttcaact	acctgggtta	aaattgaggg	360
attgttagtc	tgtggtaca	tattacacat	tcagcaaaac	aactgaaact	caactgaact	420
tgtttatact	ttgacacagg	gtctagaaaa	ggaaacaaca	atgggaggtt	gaggtcgtgt	480
ggccaaagtg	gaagttcaag	ggaagaagcc	tctctcaagg	gttccaaaca	caaagccacc	540
attcaactgtt	ggccaactca	agaaaagaat	tccaccacac	tgcttcagc	gctccctcct	600
cacttcattt	tcctatgtt	tttatgacct	ttcatttgcc	ttcattttct	acattgccac	660
cacctacttc	caccccttc	ctcaaccctt	ttcccttatt	gcatggccaa	tcaagccgaa	720
ttctgcagat	atccatcaca	tggcggcggn	tggngnaggn	ntntanaggg	cccaattc	778

<210> 28
 <211> 148
 <212> DNA
 <213> Glycine max

<400> 28

gtaatctcac	tctcacactt	tctttataca	tcgcacacca	gtgtgggtt	tttgcacacct	60
acaccgaagt	aatgccttat	aattaatggg	gttaacacat	gtccaagtcc	aatattttgt	120
tcacttattt	gaacttgaac	atgtgttag				148

<210> 29
 <211> 361
 <212> DNA
 <213> Glycine max

<400> 29

gtatcccatt	taacacaatt	tgtttcatta	acattttaaag	agaatttttt	tttcaaaata	60
gttttcgaaa	ttaagcaaat	accaagcaaa	ttgttagatc	tacgctgtt	cttgtttttaa	120
agtcaaattt	atgaccaaat	tgtcctcaca	agtccaaacc	gtccactatt	ttatttcac	180
ctactttata	gcccaattt	tcatttggtt	acttcagaaaa	agagaacccc	atttgttagta	240
aatatattat	ttagttaattt	tggtagttt	aacataaaac	atatttatgt	gcagttttgc	300
catccctcaa	aagaagatag	aaacttactc	catgttactc	tgtctatatg	taatttcaca	360
g						361

<210> 30
 <211> 36
 <212> DNA
 <213> Glycine max

<400> 30	
gcgatcgatg tatgatgcta aattaaatttgcctg	36
<210> 31	
<211> 30	
<212> DNA	
<213> Glycine max	
<400> 31	
gcggaattcc tgtgtcaaag tataaagaag	30
<210> 32	
<211> 19	
<212> DNA	
<213> Glycine max	
<400> 32	
catgcttctt gtgcttctc	19
<210> 33	
<211> 19	
<212> DNA	
<213> Glycine max	
<400> 33	
gttgatccaa ccatagtcg	19